“Our rise reflects years of commitment to building a truly comprehensive cancer center where scientific discovery and exceptional patient care advance hand in hand,” said Stephen D. Nimer, M.D., director of Sylvester. He said the center’s multidisciplinary teams are increasingly equipped to deliver experimental therapies and specialized treatments to patients with complex or difficult-to-treat cancers. This model links laboratory research with clinical practice, allowing discoveries in areas such as tumor biology, molecular diagnostics and therapeutic development to move more efficiently toward patient care.

Sylvester is the only National Cancer Institute-designated cancer center in South Florida, a designation that recognizes institutions with substantial research activity, advanced cancer programs and a commitment to reducing the burden of cancer. Its work spans basic science, population research, clinical investigation and direct treatment. This integrated structure is designed to improve the accuracy of diagnosis, identify biological differences between tumors and match patients with therapies that are more precisely suited to the molecular characteristics of their disease.

A central component of that effort is Sylvester’s academic Phase 1 Clinical Trials Program, described as the only program of its kind in South Florida. Phase 1 trials are generally the first studies in which a new drug, biologic therapy or treatment combination is tested in people. Researchers primarily evaluate safety, tolerability, dosage and how the treatment behaves in the body, although early signals of effectiveness may also emerge. For patients whose cancers have resisted standard therapies, these studies can provide access to treatments years before they become broadly available, while generating data needed for later-stage clinical development.

The center’s research capacity expanded substantially with the opening of the 12-story Kenneth C. Griffin Cancer Research Building in 2025. The facility doubled Sylvester’s research space and brought scientists, physicians, clinical investigators and data specialists into closer proximity. Such physical and organizational integration is important in translational medicine, which seeks to convert discoveries from laboratory models into diagnostic tools, clinical trials and treatments. Shared research environments can accelerate the analysis of tumor samples, the testing of candidate therapies and the development of data-driven approaches to predicting treatment response.

Sylvester is also extending cancer research and prevention beyond its main clinical facilities. Its Game Changer mobile program brings cancer screening, education and research opportunities to medically underserved communities across South Florida. Mobile outreach can help reduce barriers related to transportation, geography and access to specialty care, while screening programs may identify disease at earlier and more treatable stages. The center also leads a nationally recognized firefighter cancer initiative focused on research, prevention, screening and advocacy, addressing occupational exposures and other factors that may influence cancer risk in firefighting populations.

Additional programs target cancer survivorship and prevention. An NCI-funded effort is working to strengthen survivorship care through community health centers, where patients may receive long-term monitoring and support closer to home after completing treatment. Sylvester is also advancing lifestyle medicine and research on human papillomavirus-associated cancers. HPV can contribute to the development of several malignancies, including cervical, anal, oropharyngeal and other cancers. Combining vaccination, screening, behavioral interventions and molecular research may help reduce preventable disease and improve outcomes for people already diagnosed.

The latest rankings reflect performance across the wider UHealth system as well. Four additional programs earned national rankings, including ophthalmology, neurology and neurosurgery, geriatrics, and cardiology, heart and vascular surgery. Bascom Palmer Eye Institute retained the nation’s No. 1 position in ophthalmology for the 25th consecutive year. UHealth’s neurology and neurosurgery program ranked No. 14 nationally and includes more than 70 research and clinical faculty working across neurological subspecialties. Five other specialties—urology, diabetes and endocrinology, gastroenterology and gastrointestinal surgery, orthopedics, and pulmonology and lung surgery—received high-performing designations, placing them among the top 10% of hospitals nationwide.

Together, the results point to an expanding health system built around specialized care, research infrastructure and long-term patient management. “We are proud of what these results say about our progress, but our focus remains on what comes next,” said Dipen J. Parekh, M.D., chief executive officer of UHealth. He said the system would continue investing in people, innovation and specialized services. For Sylvester, the national rise is both a measure of recent progress and a sign of the competitive importance of connecting advanced cancer biology, early-phase clinical research, community prevention and comprehensive care within a single academic health system.

Subject of Research: Cancer research, clinical oncology, cancer prevention, Phase 1 clinical trials and translational medicine.

Article Title: Sylvester Cancer Center Rises to No. 23 Nationwide in 2026 U.S. News Rankings

News Publication Date: August 4, 2026

Web References: Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center; Kenneth C. Griffin Cancer Research Building: https://umiamihealth.org/en/locations/sylvester-comprehensive-cancer-center-kenneth-c-griffin-cancer-research-building; UHealth rankings report: https://news.med.miami.edu/uhealth-highest-us-news-hospital-rankings-2026/

References: U.S. News & World Report 2026 Best Hospitals rankings; National Cancer Institute cancer center designation information; Sylvester Comprehensive Cancer Center announcement.

Image Credits: Sylvester Comprehensive Cancer Center

Keywords: Cancer, cancer research, clinical research, oncology, Phase 1 clinical trials, translational medicine, Sylvester Comprehensive Cancer Center, UHealth, University of Miami, National Cancer Institute, cancer prevention, survivorship care

The recognition from Becker’s Hospital Review, a respected voice within healthcare analysis, highlights institutions that demonstrate unparalleled excellence in cancer research, innovative treatment modalities, and comprehensive patient care. The Mays Cancer Center’s inclusion is a testament to its sophisticated programs and the impactful outcomes it has generated for patients, particularly across the 38-county South Texas region it serves. The center’s commitment to integrating cutting-edge research with clinical practice sets a new benchmark for oncological care.

Central to the Mays Cancer Center’s distinguished status is its National Cancer Institute (NCI) designation, an elite status awarded to a select cadre of cancer centers demonstrating rigorous adherence to scientific and administrative criteria. Only four centers in Texas share this accolade, with Mays uniquely positioned as the singular NCI-designated center servicing South Texas. This status guarantees access to federally funded clinical trials and cements its role as a hub for groundbreaking research and experimental therapeutics.

Dr. Francisco Cigarroa, the senior executive vice president for health affairs and health system at The University of Texas at San Antonio, emphasized the profound significance of the designation. He framed the honor as a defining milestone that not only elevates the institution but also signifies a monumental step forward in the pursuit of transformative cancer therapies and enhanced patient outcomes on a national scale. The center exemplifies the synthesis of rigorous discovery science with compassionate patient care.

The Mays Cancer Center’s leadership under Dr. Lei Zheng, MD, PhD, the executive director, further exemplifies a culture of relentless innovation and dedication to collaborative interdisciplinary research. Dr. Zheng underscores that the accolade reflects years of strategic investments as well as the collective effort of a multidisciplinary team devoted to bridging the gap between laboratory discoveries and clinical application, ultimately delivering lifesaving therapies close to home for families in South Texas.

Established in 1974, the Mays Cancer Center has methodically evolved into a hub of cancer drug development and translational research excellence. Its multifaceted clinical programs span the continuum of oncology care, targeting a diverse array of malignancies with precision medicine approaches. These include early detection techniques, novel therapeutic regimens, and comprehensive supportive care, all underpinned by an expansive portfolio of over 180 active clinical trials.

This sprawling clinical trial network enables the Mays Cancer Center to offer patients access to some of the most innovative and emerging cancer treatments available anywhere globally. These trials are integral in assessing targeted agents, immunotherapies, and combinatorial approaches tailored to specific tumor biology, which hold promise for improving survival rates and quality of life for patients battling cancer.

Notably, the Mays Cancer Center’s impact extends beyond regional borders due to its partnership since 2017 with the MD Anderson Cancer Center, one of the nation’s foremost comprehensive cancer centers. This alliance expands treatment options and elevates the standard of care, offering patients in South Texas direct access to advanced protocols and therapies that might otherwise require travel to distant metropolitan hubs.

The center’s research efforts are rooted in a deep commitment to deciphering the molecular underpinnings of various cancers, utilizing state-of-the-art genomic sequencing and biomarker discovery to enable personalized medicine strategies. These insights fuel the development of targeted therapies that transcend traditional chemotherapy, aiming to disrupt cancer signaling pathways with heightened specificity and reduced off-target toxicity.

Furthermore, the Mays Cancer Center prioritizes cancer prevention and early detection, recognizing that these domains are critical to reducing cancer incidence and mortality. Initiatives include comprehensive community outreach programs and educational campaigns designed to elevate awareness about modifiable risk factors and promote screening adherence, particularly within underserved populations in the region.

By integrating basic science, clinical research, and community engagement, the Mays Cancer Center exemplifies a holistic approach to oncology. It strives to address disparities in healthcare access while fostering generation of novel therapies capable of transforming the cancer treatment landscape. This comprehensive strategy ensures that scientific breakthroughs translate into tangible health benefits for patients and communities alike.

The acknowledgment by Becker’s Hospital Review affirms the center’s position at the vanguard of cancer research and care. It heralds a new era where the fusion of innovative science, clinical expertise, and compassionate patient support coalesce to deliver outcomes that were once deemed unattainable. The Mays Cancer Center stands as a beacon of hope and progress in the relentless fight against cancer.

The broader implications of this recognition resonate on both local and national scales, positioning the Mays Cancer Center as a cornerstone for oncology innovation within Texas and beyond. The designation and ongoing initiatives underscore the vital role academic medical centers play in driving healthcare forward and ensuring equitable access to next-generation cancer therapies.

For those seeking more information about the transformative work being undertaken at the Mays Cancer Center, prospective patients, researchers, and collaborators are encouraged to visit their official website. The center’s digital platforms offer comprehensive resources detailing clinical programs, ongoing trials, and opportunities to engage with their pioneering research community.

Subject of Research: Cancer research, clinical oncology, translational medicine, cancer drug development, and cancer care innovation.

Article Title: Mays Cancer Center at UT Health San Antonio Earns National Acclaim for Oncology Excellence in 2025

News Publication Date: October 28, 2025

Web References:
– https://cancer.uthscsa.edu/
– https://www.beckershospitalreview.com/oncology/100-hospitals-and-health-systems-with-great-oncology-programs-2025/
– https://www.uthscsa.edu/

Keywords: Cancer, Oncology, Clinical Research, Drug Discovery, Cancer Care, Translational Medicine, National Cancer Institute, Clinical Trials, Cancer Prevention, Molecular Oncology, Cancer Drug Development, Collaborative Research

Dr. Hari’s arrival signifies a transformative step in the deployment of precision oncology in the region, as he brings a specialized expertise in nuclear oncology combined with translational science aimed at deciphering metabolic processes in cancer progression. Pennington Biomedical’s Executive Director, Dr. John Kirwan, emphasized that this addition reflects “a deep investment in the future of cancer research and patient-centered innovation,” positioning the center to compete for the esteemed National Cancer Institute (NCI) Cancer Center designation. This classification would elevate Louisiana’s status as a national leader in cancer research, leveraging Dr. Hari’s integrated clinical and laboratory research skills.

In his new role, Dr. Hari will spearhead a research program centered on nuclear medicine, an area that has seen remarkable breakthroughs through the discovery and development of theranostic agents. These agents—capable of both diagnostic imaging and targeted therapeutic delivery—offer unparalleled promise to millions of cancer patients by enhancing treatment specificity and efficacy. His research promises to deepen understanding of cancer metabolism pathways and facilitate the design of precision therapeutics that exploit metabolic vulnerabilities within tumors.

The field of nuclear oncology, where Dr. Hari’s expertise lies, is at the forefront of clinical innovation. It combines radiopharmaceuticals that deliver radioactive isotopes directly to cancer cells, enabling highly selective tumor imaging and destruction while sparing healthy tissue. This approach exemplifies the principles of precision medicine, targeting molecular and metabolic aberrations unique to individual patients’ tumors, which may revolutionize outcomes for various cancer types, including those traditionally resistant to conventional therapies.

Beyond the laboratory, Dr. Hari will dedicate a significant portion of his efforts to direct patient care through a clinical partnership with Mary Bird Perkins Cancer Center. This collaboration enhances the translational impact of his work, ensuring that laboratory discoveries rapidly inform clinical protocols and patient treatment strategies. Jodi Conachen, Chief Operating Officer at Mary Bird Perkins, recognized Dr. Hari’s leadership as integral to elevating oncology treatment standards, underscoring the importance of institutional collaboration in expanding access to cutting-edge cancer care.

As a member of the Louisiana Cancer Research Center (LCRC), Dr. Hari will integrate his nuclear medicine initiatives with ongoing statewide efforts to combat cancer’s burden. LCRC functions as a hub uniting over 200 researchers from universities and medical centers, including LSU Health New Orleans, Tulane University School of Medicine, Xavier University of Louisiana, and Ochsner Health, fostering interdisciplinary research that spans basic science to clinical applications. This network aims to accelerate cancer prevention research, early detection methods, and the transition of novel treatments into clinical settings.

His work will also support the LSU-led preparations for the forthcoming submission of the NCI Cancer Center Support Grant, a critical milestone in securing additional funding and resources to scale cancer research infrastructure in Louisiana. Collaborators such as Sven Davisson, LCRC’s Chief Administrative Officer, highlighted that Dr. Hari’s specialized knowledge in nuclear medicine will enhance the center’s research capabilities and clinical offerings, ultimately driving systemic improvements in cancer care across the state.

Dr. Hari’s academic and professional background is robust and multidisciplinary, positioning him well to impact precision oncology deeply. He received his medical degree from Kurnool Medical College, India, before pursuing doctoral studies in Clinical and Translational Science at Case Western Reserve University. Most notably, he completed a prestigious Nuclear Oncology Fellowship at Memorial Sloan Kettering Cancer Center, a global leader in cancer research and treatment. This fellowship equipped him with advanced training in radiopharmaceutical development, clinical trial execution, and molecular imaging techniques.

At Pennington Biomedical, known for its cutting-edge research into chronic diseases such as obesity, diabetes, cardiovascular disease, cancer, and dementia, Dr. Hari will join a vibrant ecosystem of over 600 research professionals engaged in clinical, population, and basic science investigations. The center’s infrastructure supports high-throughput technologies and state-of-the-art core facilities enabling interdisciplinary approaches to elucidate complex biological phenomena underpinning metabolic diseases and cancer.

Dr. Lucio Miele, Director of the LSU LCMC Health Cancer Center, articulated enthusiasm about Dr. Hari’s arrival, spotlighting the synergistic collaboration spanning multiple Louisiana institutions. This coalition embodies a model of cooperative science and clinical advancement, aiming to accelerate breakthroughs in cancer prevention, early detection, and therapeutics. In uniting research and clinical expertise across Pennington Biomedical, Mary Bird Perkins, LSU LCMC Health, LSU Health New Orleans, and the Louisiana Cancer Research Center, Louisiana is poised to make significant gains toward reducing cancer morbidity and mortality statewide.

The broader implications of Dr. Hari’s work in nuclear oncology and cancer metabolism cannot be overstated. With precision medicine increasingly becoming the standard of care, the integration of metabolic imaging and targeted radiotherapy holds promise for more personalized, less toxic, and more effective cancer treatments. As the therapeutic landscape evolves, innovations originating from Dr. Hari’s research may translate into improved survival rates and quality of life for patients, addressing cancers that have historically lacked effective targeted treatments.

Pennington Biomedical’s commitment to this initiative reflects a strategic vision to not only understand disease mechanisms at a cellular and systemic level but also to translate these discoveries into scalable health solutions. Dr. Hari’s expertise strengthens this ambition, bridging the gap between molecular science and patient-centered clinical application, and positioning the center as an epicenter for innovative cancer research and therapy development.

In summary, the recruitment of Dr. Adithya Hari represents a major milestone for Louisiana’s oncology research continuum. His cutting-edge expertise in nuclear oncology and metabolic science, coupled with robust institutional collaborations, sets the stage for transformational advancements in cancer diagnosis, management, and prevention. This integrated approach underlines the promise of precision medicine to tackle one of the world’s deadliest diseases with unprecedented focus and innovation.

Subject of Research: Cancer Metabolism, Nuclear Medicine, Precision Oncology

Article Title: Pennington Biomedical Welcomes Dr. Adithya Hari to Advance Cancer Metabolism and Nuclear Oncology Research

News Publication Date: April 21, 2024

Web References:

• Pennington Biomedical Research Center: http://www.pbrc.edu
• Mary Bird Perkins Cancer Center: https://marybird.org/
• Louisiana Cancer Research Center: https://www.louisianacancercenter.org/
• LSU LCMC Health Cancer Center: https://www.medschool.lsuhsc.edu/cancer_center/

Image Credits: Madison Page, PBRC

Keywords: Cancer, Oncology, Cancer Risk, Cancer Genetics, Cancer Metabolomics, Cancer Screening, Cancer Patients, Tumor Growth, Tumor Regression, Medical Research Facilities, Educational Facilities, Laboratories, Scientific Facilities, Education, Universities, Educational Institutions